Literature DB >> 11007671

Characterization of early IgA nephropathy.

F M Lai1, C C Szeto, P C Choi, P K Li, A W Chan, N L Tang, S F Lui, A Y Wang, K F To.   

Abstract

Histological grading of 45 patients with clinical early immunoglobulin A (IgA) nephropathy was correlated with disease progression over a median follow-up of 123 months. Clinical early IgA nephropathy was defined as a serum creatinine level of 1.3 mg/dL or less, proteinuria of 0.4 g/d or less of protein, and the absence of hypertension at the time of renal biopsy. Disease progression was related to the occurrence of impaired renal function, increased proteinuria, and hypertension. We applied a previously described chronicity-based histological grading to the renal biopsy specimen and also assessed acute glomerular lesions. Disease progression was observed in 44.4% of these patients. Forty patients (89%) showed glomerular grade 1 (GG1) and 5 patients (11%) showed GG2, but this grading did not correlate with disease progression. However, when GG1 was subdivided into GG1a (mean sclerosis per glomerulus <10%) and GG1b (mean sclerosis per glomerulus 10% to <25%), GG1a correlated with nonprogressive disease. Tubulointerstitial grade also correlated with disease progression but was associated with a low sensitivity for predicting nonprogressive disease. Hyaline arteriolosclerosis and acute glomerular lesions did not correlate with disease progression. The chronicity-based histological grading is not only applicable to clinical early IgA nephropathy, but also more importantly, it characterizes GG1a in a subset of patients with a very low risk for disease progression, which can be regarded as genuine early IgA nephropathy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11007671     DOI: 10.1053/ajkd.2000.17614

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  7 in total

1.  IgA nephropathy: is a new approach beyond proteinuria necessary?

Authors:  Eduardo Gutiérrez
Journal:  Pediatr Nephrol       Date:  2019-02-18       Impact factor: 3.714

2.  Renal expression of advanced oxidative protein products predicts progression of renal fibrosis in patients with IgA nephropathy.

Authors:  Jun Wang; Min Liang; Jie Xu; Wei Cao; Guo B Wang; Zhan M Zhou; Jian W Tian; Nan Jia; Zhenhai Zhang; Jing Nie; Youhua Liu; Fan F Hou
Journal:  Lab Invest       Date:  2014-07-28       Impact factor: 5.662

3.  Initial treatment with pulse methylprednisolone followed by short-term prednisolone and tonsillectomy for childhood IgA nephropathy.

Authors:  Akifumi Yamada; Shuichiro Fujinaga; Koji Sakuraya; Asanuma Satoshi; Daishi Hirano
Journal:  Clin Exp Nephrol       Date:  2018-03-08       Impact factor: 2.801

4.  Long-term outcomes of IgA nephropathy presenting with minimal or no proteinuria.

Authors:  Eduardo Gutiérrez; Isabel Zamora; José Antonio Ballarín; Yolanda Arce; Sara Jiménez; Carlos Quereda; Teresa Olea; Jorge Martínez-Ara; Alfons Segarra; Carmen Bernis; Asunción García; Marian Goicoechea; Soledad García de Vinuesa; Jorge Rojas-Rivera; Manuel Praga
Journal:  J Am Soc Nephrol       Date:  2012-09-06       Impact factor: 10.121

5.  Long-term prognosis of IgA nephropathy presenting with minimal or no proteinuria: A single center experience.

Authors:  N Imai; S Shirai; T Yasuda; Y Shibagaki; K Kimura
Journal:  Indian J Nephrol       Date:  2016 Mar-Apr

6.  Significance of tonsillectomy combined with steroid pulse therapy for IgA nephropathy with mild proteinuria.

Authors:  Hiroyuki Komatsu; Yuji Sato; Tetsu Miyamoto; Masahito Tamura; Takeshi Nakata; Tadashi Tomo; Tomoya Nishino; Masanobu Miyazaki; Shouichi Fujimoto
Journal:  Clin Exp Nephrol       Date:  2015-06-30       Impact factor: 2.801

7.  Long-term prognosis of clinically early IgA nephropathy is not always favorable.

Authors:  Hajeong Lee; Jin Ho Hwang; Jin Ho Paik; Hyun Jin Ryu; Dong Ki Kim; Ho Jun Chin; Yun Kyu Oh; Kwon Wook Joo; Chun Soo Lim; Yon Su Kim; Jung Pyo Lee
Journal:  BMC Nephrol       Date:  2014-06-19       Impact factor: 2.388

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.